Zai Lab (ZLAB) Cash & Equivalents (2016 - 2026)

Zai Lab (ZLAB) has reported Cash & Equivalents for 11 consecutive years, with $651.3 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 13.99% year-over-year to $651.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.3 million (down 13.99% YoY) and the FY2025 annual result came in at $679.6 million, up 51.13% from the prior year.
• Cash & Equivalents retreated to $651.3 million in Q1 2026 per ZLAB's latest filing, from $679.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ZLAB reached as high as $1.1 billion in Q3 2022 and fell as low as $449.7 million in Q4 2024.
• A 5-year average of $756.3 million and a median of $732.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 61.46% — and 2025, when it jumped 51.13%.
• Year by year, Cash & Equivalents stood at $1.0 billion in 2022, then retreated by 21.65% to $790.2 million in 2023, then tumbled by 43.09% to $449.7 million in 2024, then soared by 51.13% to $679.6 million in 2025, then declined by 4.16% to $651.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $651.3 million, $679.6 million, and $717.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.